Understand the source comparison
Peptides for NASH Liver: Clinical Comparison
GLP-1 Agonist (Semaglutide 2.4mg) GLP-1 receptor only 33–40% relative reduction 59% (vs 17% placebo) No significant change at 72 weeks Proven NASH resolution. Fibrosis benefit requires longer observation GIP/GLP-1 Dual Agonist (Tirzepatide 15mg) GLP-1 + GIP re
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 Agonist (Semaglutide 2.4mg)
- GLP-1 receptor only
- 33–40% relative reduction
- 59% (vs 17% placebo)
- No significant change at 72 weeks
- Proven NASH resolution. Fibrosis benefit requires longer observation
- GIP/GLP-1 Dual Agonist (Tirzepatide 15mg)
- GLP-1 + GIP receptors
- 74% relative reduction
- 62% achieved ≥1-stage fibrosis improvement
- Significant at 52 weeks
- Superior steatosis clearance and earlier fibrosis signal than monotherapy
- GLP-1/GIP/Glucagon Triple Agonist (Survodutide)
- GLP-1 + GIP + glucagon receptors
- Phase 2 ongoing. Preliminary 83% reduction
- Data pending
- Highest hepatic fat oxidation potential. FDA fast-track designation granted
- Thymosin Beta-4 Fragment (Thymalin)
- Immune modulation, hepatocyte regeneration
- Not quantified in NASH trials
- No RCT data
- Preclinical fibrosis models show ECM remodelling
- Adjunctive immune regulation. Not a standalone NASH therapy